Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Pfizer has been the undisputed leader in the pneumococcal vaccine market for years, gradually adding new versions of Prevnar that expand the number of serotypes covered, but analysts think that ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

making administration smoother compared to Prevnar 13. PAHO, a regional office for the Americas arm of the World Health Organization, views the importance of large-scale vaccine production and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Key pipeline assets include the CDK4 inhibitor, the SV and PD-L1 ADCs, and the next-generation Prevnar vaccine, all of which have the potential to be blockbuster products. Pfizer Inc. (NYSE ...